Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study

References

• Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheu-matoid arthritis: an international long-term view. Semin Arthritis Rheum. 2000;29(5):305–20.
   PubMed Web of Science ®Google Scholar
• Cooper NJ. Economic burden of rheumatoid arthritis: a system-atic review. Rheumatology (Oxford). 2000;39(1):28–33.
   PubMed Web of Science ®Google Scholar
• Weaver AL. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2004;43\(Suppl 3):iii17–23.
   Google Scholar
• Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JW, et al. Updated consensus statement on biological agents, specifically tumor necrosis factor alpha (TNF{ alpha}) blocking agents and interleukin-1 receptor antagonist (IL- lra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis. 2005;64\(Suppl 4):iv2–14.
   Google Scholar
• Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, Tan-iguchi A, et al. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. Mod Rheumatol. 2007;17(4):283–9.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Tohma S. Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol. 2006;16(2):75–6.
   PubMedGoogle Scholar
• Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi A, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum. 2003;49(6):784–8.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Saito A, Kamitsuji S, Yamada T, Nakajima A, Tan-iguchi A, et al. Impact of shoulder, elbow, and knee joint involvement on assessment of rheumatoid arthritis using the American College of Rheumatology Core Data Set. Arthritis Rheum. 2005;53(6):864–71.
   Google Scholar
• Nakajima A, Kamitsuji S, Saito A, Tanaka E, Nishimura K, Horikawa N, et al. Disability and patient's appraisal of general health contribute to depressed mood in rheumatoid arthritis in a large clinical study in Japan. Mod Rheumatol. 2006;16(3):151–7.
   PubMedGoogle Scholar
• Tanaka E, Inoue E, Kawaguchi Y, Tomatsu T, Yamanaka H, Hara M, et al. Acceptability and usefulness of mizoribine in the management of rheumatoid arthritis in methotrexate-refractory patients and elderly patients, based on analysis of data from a large-scale observational cohort study. Mod Rheumatol. 2006; 16(4) : 214–9.
   PubMedGoogle Scholar
• Yamada T, Nakajima A, Inoue E, Tanaka E, Hara M, Tomatsu T, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis. 2006;65(12):1661–3.
   PubMed Web of Science ®Google Scholar
• Furuya T, Kotake S, Inoue E, Nanke Y, Yago T, Kobashigawa T, et al. Risk factors associated with incident clinical vertebral and nonvertebral fractures in Japanese women with rheumatoid arthritis: a prospective 54-month observational study. J Rheu-matol. 2007;34(2):303–10.
   PubMed Web of Science ®Google Scholar
• Iikuni N, Nakajima A, Inoue E, Tanaka E, Okamoto H, Hara M, et al. What's in season for rheumatoid arthritis patients? Seasonal fluctuations in disease activity. Rheumatology (Oxford). 2007;46(5):846–8.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Mannalithara A, Inoue E, Hara M, Tomatsu T, Kamatani N, Singh G, Yamanaka H. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability. Ann Rheum Dis. 2008;67(8):1153–8.
   PubMed Web of Science ®Google Scholar
• Iikuni N, Inoue E, Tanaka E, Hara M, Tomatsu T, Kamatani N, et al. Low disease activity state with corticosteroid may not represent 'true' low disease activity state in patients with rheu-matoid arthritis. Rheumatology (Oxford). 2008;47(4):519–21.
   PubMed Web of Science ®Google Scholar
• van der Heijde DM, van't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the devel-opment of a disease activity score. Ann Rheum Dis. 1990;49(11):916–20.
   Google Scholar
• Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–8.
   Google Scholar
• Sekiguchi N, Kameda H, Amano K, Takeuchi T. Efficacy and safety of bucillamine, a D-penicillamine analogue, in patients with active rheumatoid arthritis. Mod Rheumatol. 2006;16(2):85–91.
   PubMedGoogle Scholar
• Nakamura H, Ueki Y, Sakito S, Matsumoto K, Yam M, Miyake S, et al. Clinical effects of actarit in rheumatoid arthritis: improvement of early disease activity mediated by reduction of serum concentrations of nitric oxide. Clin Exp Rheumatol. 2000;18(4):445–50.
   PubMed Web of Science ®Google Scholar
• Lubeck DP. A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings. Pharmacoeconom-ics. 2001;19(8):811–8.
   PubMed Web of Science ®Google Scholar
• Lanes SF, Lanza LL, Radensky PW, Yood RA, Meenan RF, Walker AM, et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum. 1997;40(8):1475–81.
   PubMed Web of Science ®Google Scholar
• Mithal A, Yamanaka H, Tanaka E, Nakajima A, Kamatani N. Medical costs for care of rheumatoid arthritis in Japan. In: ISPOR first Asia-Pacific conference; 2003 September 1–3; Kobe, Japan.
   Google Scholar
• Yamanaka H, Mithal A, Tanaka E, Nakajima A, Kamatani N. Medical costs are significantly associated with disability levels in rheumatoid arthritis in Japan. In: ISPOR first Asia-Pacific con-ference; 2003 September 1–3; Kobe, Japan.
   Google Scholar
• Kobelt G, Eberhardt K, Jönsson L, Jönsson B. Economic con-sequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 1999;42(2):347–56.
   PubMed Web of Science ®Google Scholar
• Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum. 1999;42(6):1209–18.
   PubMed Web of Science ®Google Scholar
• Fries JF. Safety, cost and effectiveness issues with disease modifying anti-rheumatic drugs in rheumatoid arthritis. Ann Rheum Dis. 1999;58(Suppl 1):186–9.
   PubMed Web of Science ®Google Scholar
• Lajas C, Abasolo L, B ellaj del B, Hernández-Garcia C, Carmona L, Vargas E, etal. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum. 2003;49(1):64–70.
   PubMed Web of Science ®Google Scholar
• Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum. 2003;48(10): 2750–62.
   PubMed Web of Science ®Google Scholar